Report: Achieving launch excellence in the challenging healthcare markets of today
|10th December 2018
Healthcare markets are becoming more competitive and complex. The sheer number of products coming off patent in the next five years, coupled with the growing healthcare spend and the number of players entering the healthcare space, mean it's clear pharma launches are becoming more challenging.
Adding to the pressure is the evolving networks of stakeholders who each have a differing needs and pain points and often communicate using novel digital channels.
However, while the market can seem overwhelming, these challenges provide pharma organisations with an opportunity to meet the unmet needs of customers through clearer and more targeted marketing, and more streamlined launches.
This in-depth report was created in collaboration with Pharma Intelligence and is based on our significant experience in this area. It features interviews with senior leaders and primary market research, as well as giving key recommendations for achieving launch success in challenging markets.
Download the white paper to learn:
- The characteristics of launch excellence evidenced by successful launches from the last two years
- How to transform the operating model to ensure market responsiveness
- How you can re-focus your brand planning to maximise success.
Precision paediatrics: Treating patients with CAR-T
|9th July 2019
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
What does it mean to be an agile organisation
|27th June 2019
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Battling breast cancer with precision medicine (Part 2)
|20th June 2019
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.